Frontlight ResearchEarly access
CompletedPhase 2
Efficacy of early intravenous high-dose vitamin C in post-cardiac arrest shock: a multicenter, randomized controled to standard treatment, open label trial.
Key facts
- Who runs it
- Centre Hospitalier Bethune Beuvry
- Where
- France14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 234 people enrolled
- Started
- 27 Dec 2023
- Ended
- 14 Jul 2026
- Type of study
- Interventional
- Record updated
- 23 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- patients still comatose (Glasgow coma scale < 8)
- an OHCA of presumed cardiac origin with ROSC < 60 min
- treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg
Who cannot take part
- patients already treated with vit-C
- pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min)
- moribound or chronic disease (life expectancy <1 an)
- OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc..)
- Hypersensitivity of active substance or méthyl parahydroxybenzoate or dipropyl
- inclusion in another interventional study in cardiac arrest or post CA
- Contraindication to vitamine C (glucose-6-phosphate deshydrogenase deficiency; hemochromatosis)
- minor
- Patient with legal protective measures
- Patient not covered by French national health insurance
- known vit-C deficit
- Patient with derpived freedom
- Hyperoxaluria
- Hystory of urolithiasis
- pregnant women
- interval between OHCA and randomization > 4 hours
- extracorporeal circulatory assistance requirement in the first 4 hours after OHCA
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Our main objective is to assess the efficacy of IV high-dose vit-C to reduce the need for vasopressor within the first 3 days in patients who suffered from an OHCA with a post-CA shock.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 23 September 2026